Proportion of Patients with a ≥25% Improvement from Baseline ABC-CFXS Subscales for (A) Patients Who Completed Period 1 and (B) Patients Who Entered Period 2

FXS Proportion of patients with a 25% improvement from baseline ABC-CFXS Subscales

Proportion of Patients with a ≥25% Improvement from Baseline ABC-CFXS Subscales for (A) Patients Who Completed Period 1 and (B) Patients Who Entered Period 2

Format

PNG

Source

Zynerba Pharmaceuticals, Inc.

Downloads